Medications for Severe Combined Immunodeficiency

5 results

  • bivigam

    (Immune Globulin Intravenous (Human) 10%)
    ADMA Biologics, Inc.
    BIVIGAM is indicated for treating primary humoral immunodeficiency (PI) in adults and children aged 2 years and older. It addresses conditions such as common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • cutaquig

    (immunoglobulin G)
    Pfizer Laboratories Div Pfizer Inc
    CUTAQUIG is indicated for replacement therapy in primary humoral immunodeficiency in adults and children aged 2 and older. Conditions include common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • cuvitru

    (Immune Globulin Subcutaneous (Human))
    Takeda Pharmaceuticals America, Inc.
    CUVITRU is indicated for replacement therapy in primary humoral immunodeficiency (PI) in patients aged two years and older. Conditions treated include common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • flebogamma

    (Immune Globulin (Human))
    GRIFOLS USA, LLC
    Flebogamma 5% DIF is an intravenous immune globulin indicated for adults and children aged 2 and older to treat primary immunodeficiency, including conditions like common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency, and Wiskott-Aldrich syndrome.

  • yimmugo

    (immune globulin intravenous, human - dira)
    Biotest AG
    YIMMUGO is indicated for treating primary humoral immunodeficiency (PI) in patients aged 2 and older, including conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).